Outcomes of long-term responders to immunotherapy in the treatment of advanced non-small cell lung cancer (NSCLC). A retrospective regional study

RECOMMENDED

Lung, Respiratory and Thoracic Cancer

Comparison of long-term survival between nivolumab plus ipilimumab with chemotherapy and pembrolizumab with chemotherapy in advanced non-small cell lung cancer: A multicenter retrospective cohort study

★ 1 Recommended by Dr Martin Frey, Faculty Member

★ 1 Recommended by Dr Marcus Hesse, Faculty Member

Lung Cancer

Kinehara Y, Matsumoto K, Shiroyama T, Komuta K, Tamiya M, Nishino K, Tamiya A, Kuge T, Uchida J, Suzuki H, Yamamoto S, Tobita S, Niki T, Tetsumoto S, Morimura O, Osa A, Minami T, Nagatomo I, Takeda Y, Kijima T, Kumanogoh A

doi: 10.1016/j.lungcan.2026.109336

Lung, Respiratory and Thoracic Cancer

Treatment Sequencing and Immunotherapy Rechallenge in Advanced Non-Small-Cell Lung Cancer: Final 24-Month Real-World Results from the French LIST Study

Oncol Ther

Godbert B, Gobbini E, Khalife Y, Decroisette C, Brellier F, Lena H, Fleuriet A, Zysman M, Egenod T, Girard N

doi: 10.1007/s40487-026-00437-8

RECOMMENDED

Lung, Respiratory and Thoracic Cancer

Real-world outcomes of immunotherapy discontinuation at two years in advanced non-small cell lung cancer: Final results of the I-STOP study

★ 2 Recommended by Dr Martin Frey, Faculty Member

★ 1 Recommended by Dr Marcus Hesse, Faculty Member

Eur J Cancer

Gemelli M, Sala L, Morabito A, Sforza V, Cortellini A, La Cava G, Bertolini F, Guaitoli G, Carnio S, Novello S, Leonetti A, Tiseo M, Mazzoni F, Cosso F, Macerelli M, Membrino A, Metro G, Chiari R, Genova C, Berardi R, Tassistro E, Antolini L, Cortinovis DL

doi: 10.1016/j.ejca.2026.116579

Lung, Respiratory and Thoracic CancerCOVID-19

Treatment and outcomes of limited stage small cell lung cancer in the Canadian small cell lung cancer database (CASCADE)

Lung Cancer

Phillips WJ, Zhan LJ, Chowdhury D, Gill J, Sun A, Rittberg R, Cohen V, Gibson AJW, Yan M, Liwski D, Surapaneni S, D'Amours MF, Yu FPS, Kim Y, Qadeer RA, Dawe DE, Agulnik J, Navani V, Fung AS, Snow S, Kuruvilla S, Ho C, Lok BH, Liu G, Wheatley-Price P, Moore S

doi: 10.1016/j.lungcan.2025.108840

Lung, Respiratory and Thoracic Cancer

First-line treatment patterns and real-world outcomes in patients with advanced KRAS-mutated non-small cell lung cancer with high unmet need

Lung Cancer

Barlesi F, Skoulidis F, Solomon B, Lee J, Jassim R, Gupta R, Mesa-Frias M, Felip E

doi: 10.1016/j.lungcan.2026.109471

Lung, Respiratory and Thoracic Cancer

Radiotherapy for Unresectable Locally Advanced Non-Small Cell Lung Cancer: A Practical Multidisciplinary Approach to Challenging Scenarios from the International Association for the Study of Lung Cancer (IASLC) Advanced Radiation Technology (ART) Subcommittee

J Thorac Oncol

Zhu H, Al Saifi S, Bahig H, Cooper A, Abrão FC, Corrales L, Faivre-Finn C, Filippi AR, Fitzgerald B, Khosla D, Lam VK, Le X, Menezes V, Newsom-Davis T, Qin A, Putora PM, Munoz-Schuffenegger P, Siva S, Yu NY, Louie AV

doi: 10.1016/j.jtho.2025.11.006

Lung, Respiratory and Thoracic Cancer

Mutation testing, treatment patterns, and outcomes in patients with unresectable stage III EGFR-mutated non-small cell lung cancer treated with chemoradiotherapy: Final analysis of a global real-world study

Lung Cancer

Ahn MJ, Lin SH, Yang CT, Lee JB, Neal JW, Okishio K, Nishino K, Smith D, Rauter M, Jimenez M, Nasirova F, Kim Y

doi: 10.1016/j.lungcan.2025.108748

Lung, Respiratory and Thoracic Cancer

Real-world clinical characteristics and outcomes in patients with HER2-mutant non-small cell lung cancer (NSCLC) who received second-line treatment: A nationwide database analysis in Japan

Lung Cancer

Uehara Y, Ikegami M, Kohsaka S, Kimura H, Mizushima M, Okuma Y

doi: 10.1016/j.lungcan.2026.109491

COMMENTED

Lung, Respiratory and Thoracic Cancer

Outcomes and Treatments of Patients With Non-Small Cell Lung Cancer Who Received Pembrolizumab

★ 2 Recommended by Dr Martin Frey, Faculty Member

★ 3 Recommended and commented by Dr Marcus Hesse, Faculty Member

JAMA Oncol

Rousseau A, Foulon S, Planchard D, Remon J, Barlesi F, Lavaud P, Frelaut M, Aldea M, Parisi C, Gazzah A, Le Pechoux C, Botticella A, Levy A, Simon-Tillaux N, Michiels S, Besse B

doi: 10.1001/jamaoncol.2026.0669

Related content

Comparison of long-term survival between nivolumab plus ipilimumab with chemotherapy and pembrolizumab with chemotherapy in advanced non-small cell lung cancer: A multicenter retrospective cohort study

Treatment Sequencing and Immunotherapy Rechallenge in Advanced Non-Small-Cell Lung Cancer: Final 24-Month Real-World Results from the French LIST Study

Real-world outcomes of immunotherapy discontinuation at two years in advanced non-small cell lung cancer: Final results of the I-STOP study

Treatment and outcomes of limited stage small cell lung cancer in the Canadian small cell lung cancer database (CASCADE)

First-line treatment patterns and real-world outcomes in patients with advanced KRAS-mutated non-small cell lung cancer with high unmet need

Radiotherapy for Unresectable Locally Advanced Non-Small Cell Lung Cancer: A Practical Multidisciplinary Approach to Challenging Scenarios from the International Association for the Study of Lung Cancer (IASLC) Advanced Radiation Technology (ART) Subcommittee

Mutation testing, treatment patterns, and outcomes in patients with unresectable stage III EGFR-mutated non-small cell lung cancer treated with chemoradiotherapy: Final analysis of a global real-world study

Real-world clinical characteristics and outcomes in patients with HER2-mutant non-small cell lung cancer (NSCLC) who received second-line treatment: A nationwide database analysis in Japan

Outcomes and Treatments of Patients With Non-Small Cell Lung Cancer Who Received Pembrolizumab